Acute and Subacute Effects of EV Iron Sucrose on Endothelial Functions in Hemodialysis Patients

Figures & data

Table 1. Demographic data of HD patients and controls.

	Patient	Control	p-Value
M/F^a	6/9	2/14	>0.05
Age (years)^b	61 (54–68)	42 (31–46.5)	<0.01
Systolic blood pressure(mmHg)^c	118.66 ± 12.46	114.37 ± 16.32	>0.05
Diastolic blood pressure(mmHg)^c	78.67 ± 9.90	76.25 ± 8.85	>0.05
Mean arterial blood pressure(mmHg)^c	92.15 ± 10.53	88.96 ± 10.94	>0.05
BMI (kgm^2)^c	25.77 ± 4.31	25.44 ± 0. 29	>0.05

Notes: ^aChi-square (n); ^bMann–Whitney U test (median Q1–Q3); ^cindependent samples t-test (mean ± SD); M: male, F: female, BMI: body mass index.

Table 2. Comparison of pretreatment values of patients and controls.

	Patient (n = 15)	Control (n = 16)	p-Value
Hb (g/dl)^a	10.53 ± 1.40	9.91 ± 2.19	>0.05
Htc (%)^a	31.56 ± 4.80	30.18 ± 5.39	>0.05
Fe (mg/dL)^b	35 (25–52)	17.5 (13–44.5)	<0.05
Saturation (%)^b	13 (11–19)	3.7 (2.72–8.75)	<0.001
TIBC^a	258.60 ± 74.27	438.56 ± 95.72	<0.001
Transferrine (mg/dL)^a	207.33± 59.39	350.69 ± 76.81	<0.001
Ferritin (ng/mL)^a	143.0 ± 83.99	5.30 ± 3.86	<0.001
BUN (mg/dL)^b	42 (35–64)	11 (9.25–13)	<0.01
Cr (mg/dL)^a	6.28 ± 1.97	0.7 ± 0.15	<0.001
Albumin (g/dL)^b	4 (3.8–4.5)	4.4 (4.3–4.73)	<0.05
Calcium (mg/dL)^a	9.06 ± 0.84	9.34 ± 0.41	>0.05
Phosphorus (mg/dL)^a	4.77 ± 1.61	3.41 ± 0.59	<0.01
PTH (pg/mL)	281 (139–538)	47 (33.25–66.75)	<0.001
TG (mg/dL)^b	143 (102–178)	101 (75.75–145.5)	<0.05
TC (mg/dL)^b	164 (152–218)	169.5 (147.75–185.5)	>0.05
HDL-C (mg/dL)^a	47.93 ± 18.75	48.63 ± 13.96	>0.05
LDL-C (mg/dL)^b	99 (95–140)	105 (83–114)	>0.05
Ca × P^a	43 ± 13.91	31.93 ± 6.42	<0.05
EDV %^b	6.25 (4.76–11.43)	10.53 (6.56–20)	<0.05
NIV (%)^b	14.29 (12.5–20.51)	21.11 (14.31–29.94)	>0.05

Notes: ^aIndependent sample t-test (mean ± SD); ^bMann–Whitney U test (median Q1–Q3).

Hb, hemoglobin; Htc, hematocrit; Fe, serum iron; TIBC, total iron-binding capacity; BUN, blood urea nitrogen; Cr, creatinine; PTH, parathormone; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Ca × P, calcium × phosphorus; EDV, endothelium-dependent vasodilatation; NIV, nitroglycerine-induced vasodilatation.

Table 3. Percent changes of EDV and NIV in HD patients and control subjects.

	n	Basal	Acute	Subacute	p-Value
HD patient EDV %^a	15	7.51 ± 4.12	5.88 ± 4.34	8.25±7 50	>0.05
Control group EDV %^a	16	13.22 ± 8.68	9.65 ± 7.64	8.87 ± 5.87	>0.05
HD Patient NIV %^a	15	16.54 ± 8.43	13.54 ± 8.58	12.51 ± 9.17	>0.05
Control group NIV %^b	16	21.11 (14.67–28.85)	16.15 (12.66–26.30)	17.09 (13.36–28.08)	>0.05

Notes: ^aOne-way repeated measures analysis of variance (mean ± SD); ^bFriedman repeated measures analysis of variance on ranks (median Q1–Q3).

EDV, endothelium-dependent vasodilatation; NIV, nitroglycerin-induced vasodilatation; HD, hemodialysis.

Table 4. Hb and iron status of HD patients before and after 1 g EV iron therapy.

	Before treatment	After treatment	p-Value
Hb (g/dL)^a	10.53 ± 1.40	11.53 ± 0.42	<0.05
Htc (%)^a	31.56 ± 4.80	34.0 ± 5.19	>0.05
Fe (mg/dL)	35 (25–52)	39 (25–71)	>0.05
Saturation (%)^b	13 (11–19)	16 (1–33)	>0.05
Transferrin (mg/dL)^a	207.33 ± 59.39	171.80±41.48	<0.05
TIBC^a	258.62 ±74.27	214.2 ± 51.88	<0.05
Ferritin (ng/mL)^a	143.21 ± 83.99	460.06 ± 263.04	<0.001

Notes: ^aPaired samples t-test (mean ± SD); ^bWilcoxon test (median Q1–Q3).

HD, hemodialysis; Hb, hemoglobin; Htc, hematocrit; Fe, serum iron; TIBC, total iron-binding capacity.

Table 5. Hb and iron status of control subjects before and after 1 g EV iron therapy.

	Before treatment	After treatment	p-Value
Hb (g/dL)^a	9.91 ± 2.19	11.93 ± 1.04	<0.001
Htc (%)^a	30.18 ± 5.19	35.91 ± 2.78	<0.001
Fe (mg/dL)^b	17.5 (13–44.5)	58 (31.25–79.5)	<0.001
Saturation (%)^b	3.7 (2.72–8.75)	15.5 (9.75–30.25)	<0.001
Transferrin (mg/dL)^a	350.69±76.81	273.38 ± 55.17	<0.001
TIBC^a	438.56 ± 95.72	330.31 ± 83.51	<0.001
Ferritin (ng/mL)^a	5.30 ± 3.86	165.12 ± 99.63	<0.001

Notes: ^aPaired samples t-test (mean ± SD); ^bWilcoxon test (median Q1–Q3).

EV, endovenous; Hb, hemoglobin; Htc, hematocrit; Fe, serum iron; TIBC, total iron-binding capacity.